載入中
NYSEHealthcareDrug Manufacturers - General
最新資料
US$142.79
+US$0.85 · +0.60%
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
前收盤價
US$142.79
+US$0.85 · +0.60%
盤前
US$142.07
−US$0.72 · -0.50%
10月8日 上午9:28 ET
盤中時間採用ET。市場資料可能有所延遲。
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
日內區間
目前US$142.79
52週區間
目前US$142.79
盤中時間採用ET。市場資料可能有所延遲。
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
日內區間
目前US$142.79
52週區間
目前US$142.79
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 649.26億 USD | 641.68億 USD | 601.15億 USD | 592.83億 USD | 487.04億 USD |
| 銷貨成本 | 181.95億 USD | 151.93億 USD | 161.26億 USD | 174.11億 USD | 136.26億 USD |
| 毛利 | 467.31億 USD | 489.75億 USD | 439.89億 USD | 418.72億 USD | 350.78億 USD |
| 研究與開發 | 125.14億 USD | 179.38億 USD | 305.31億 USD | 135.48億 USD | 122.45億 USD |
| 銷售、一般及管理費用 | 107.31億 USD | 101億 USD | 98.84億 USD | 96.69億 USD | 94.03億 USD |
| 營業費用 | 232.45億 USD | 287.54億 USD | 410.35億 USD | 235.9億 USD | 218.79億 USD |
| 利息收入 | 3.43億 USD | 4.15億 USD | 3.65億 USD | 1.57億 USD | 3600萬 USD |
| 利息支出 | 13.57億 USD | 12.71億 USD | 11.46億 USD | 9.62億 USD | 8.06億 USD |
| 折舊和攤銷 | 58.38億 USD | 44.99億 USD | 38.72億 USD | 39.09億 USD | 32.14億 USD |
| 營業利益 | 234.86億 USD | 202.21億 USD | 29.54億 USD | 182.82億 USD | 131.99億 USD |
| 淨利 | 182.54億 USD | 171.17億 USD | 3.65億 USD | 145.19億 USD | 130.49億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$158.78
上漲空間 11.20%年度分割調整後的每股現金分配。
US$3.28
2025年（完整年度）+25.7% 自從 2021
2026年（部分年度）：US$2.55
US$2.6102
2,021
US$2.80
2,022
US$2.96
2,023
US$3.12
2,024
US$3.28
2,025
US$2.55
2,026*
* 在現有股息歷史記錄中，該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月15日 | US$0.85Quarterly | 2026年9月15日 | 2026年10月7日 |
股息 | 2026年6月15日 | US$0.85Quarterly | 2026年6月15日 | 2026年7月8日 |
股息 | 2026年3月16日 | US$0.85Quarterly | 2026年3月16日 | 2026年4月7日 |
股息 | 2025年12月15日 | US$0.85Quarterly | 2025年12月15日 | 2026年1月8日 |
股息 | 2025年9月15日 | US$0.81Quarterly | 2025年9月15日 | 2025年10月7日 |
股息 | 2025年6月16日 | US$0.81Quarterly | 2025年6月16日 | 2025年7月8日 |
除息 2026年9月15日
US$0.85
Quarterly
2026年9月15日登記 · 支付日 2026年10月7日
除息 2026年6月15日
US$0.85
Quarterly
2026年6月15日登記 · 支付日 2026年7月8日
除息 2026年3月16日
US$0.85
Quarterly
2026年3月16日登記 · 支付日 2026年4月7日
除息 2025年12月15日
US$0.85
Quarterly
2025年12月15日登記 · 支付日 2026年1月8日
除息 2025年9月15日
US$0.81
Quarterly
2025年9月15日登記 · 支付日 2025年10月7日
除息 2025年6月16日
US$0.81
Quarterly
2025年6月16日登記 · 支付日 2025年7月8日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T6739.58億0.52%129.41兆 JPY0.09%¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI115.99億0.49%2.3兆 USD0.03%US$381.03-0.40%
Vanguard S&P 500 ETFVOO96.94億0.55%1.8兆 USD0.03%US$714.34-0.26%
iShares Core S&P 500 ETFIVV46.66億0.52%8996.25億 USD0.03%US$780.58-0.25%
Schwab U.S. Dividend Equity ETFSCHD43.04億3.96%1086.81億 USD0.06%US$32.65-0.62%
State Street SPDR S&P 500 ETFSPY42.56億0.52%8190.39億 USD0.09%US$777.22-0.24%
Vanguard Morningstar Value ETFVTV34.88億1.33%2624億 USD0.03%US$218.21-0.37%
State Street Health Care Select Sector SPDR ETFXLV24.89億5.76%431.09億 USD0.08%US$168.81+1.03%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOiShares Core S&P 500 ETFIVVSchwab U.S. Dividend Equity ETFSCHDState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
